An investigation on behalf of current long term investors in OHR Pharmaceutical Inc (NASDAQ:OHRP) shares over possible breaches of fiduciary duty by certain officers and directors was announced.
San Diego, CA -- (SBWIRE) -- 06/19/2018 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of OHR Pharmaceutical Inc (NASDAQ:OHRP was announced.
Investors who are investors in OHR Pharmaceutical Inc (NASDAQ:OHRP) shares, have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm for investors in NASDAQ:OHRP stocks follows a lawsuit filed against OHR Pharmaceutical over alleged securities laws violations. The investigation on behalf of investors in NASDAQ:OHRP stocks, concerns whether certain OHR Pharmaceutical directors are liable in connection with the allegations made in that lawsuit.
The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that OHR Pharmaceutical Inc's lead product Squalamine would not produce vision improvements and was commercially not viable, and that as a result of the foregoing, Defendants' statements about OHR Pharmaceutical Inc's business, operations, and prospects were misleading and/or lacked a reasonable basis.
Those who purchased shares of OHR Pharmaceutical Inc (NASDAQ:OHRP) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels